IPSEN (OTCMKTS:IPSEY) Shares Gap Up – Should You Buy?

IPSEN (OTCMKTS:IPSEY)’s stock price gapped up before the market opened on Tuesday . The stock had previously closed at $43.85, but opened at $46.50. IPSEN shares last traded at $46.50, with a volume of 153 shares traded.

Analysts Set New Price Targets

Several analysts have issued reports on the company. HC Wainwright started coverage on IPSEN in a research note on Friday, June 5th. They issued a “buy” rating on the stock. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of IPSEN in a report on Thursday, May 14th. Finally, Zacks Research raised IPSEN to a “hold” rating in a research report on Friday, May 29th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, IPSEN presently has a consensus rating of “Hold”.

IPSEN Price Performance

The firm’s 50 day simple moving average is $47.53 and its 200-day simple moving average is $43.40.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).